Affinage

FBXO45

F-box/SPRY domain-containing protein 1 · UniProt P0C2W1

Length
286 aa
Mass
30.6 kDa
Annotated
2026-04-28
34 papers in source corpus 23 papers cited in narrative 23 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FBXO45 is an atypical F-box protein that functions as the substrate-recognition subunit of a non-canonical SKP1–PAM/MYCBP2–FBXO45 (SPF) E3 ubiquitin ligase complex, directing ubiquitination and degradation of a broad spectrum of substrates to control neuronal development, synaptic transmission, cell-cycle progression, EMT, innate immunity, and viral restriction. Unlike canonical SCF complexes, FBXO45 cannot bind CUL1 and instead pairs with the RING-type ligase PAM/MYCBP2; it recruits substrates through its SPRY domain (e.g., Par-4, USP49, FBXW7, N-cadherin) or F-box domain (e.g., Snai1, Twist1), targeting them for K48- or K6-linked polyubiquitination and proteasomal degradation (PMID:19398581, PMID:25460509, PMID:35838331). In the nervous system, FBXO45 degrades Munc13-1 to regulate synaptic vesicle priming and excitatory neurotransmission and interacts with N-cadherin extracellularly to promote radial neuronal migration (PMID:19996097, PMID:32341084, PMID:30042425). Beyond its canonical degradative roles, FBXO45 recruits the phosphatase PPP6C to UPF1 during S phase to stabilize replication-dependent histone mRNAs—ensuring adequate histone supply for chromatin assembly—and its loss causes genomic instability and tumorigenesis; it also directs HIV-1 Tat to p62/SQSTM1-mediated autophagic degradation (PMID:39672818, PMID:39936917).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2009 High

    Establishing that FBXO45 forms a non-canonical E3 ligase complex with PAM/MYCBP2 instead of CUL1 resolved how an F-box protein could function outside the SCF framework and linked it to neuronal development and migration.

    Evidence Proteomics/mass spectrometry, co-IP, and Fbxo45 knockout mice showing neuronal migration and synapse defects

    PMID:19398581

    Open questions at the time
    • Structure of the SKP1-PAM-FBXO45 ternary complex not determined
    • Mechanism by which FBXO45 is excluded from CUL1 binding incompletely defined at the structural level
  2. 2009 High

    Identification of p73 and Munc13-1 as direct FBXO45 substrates established that the SPF complex controls both apoptosis (p53-independent cell death via p73 stabilization) and synaptic vesicle priming (via Munc13-1 turnover).

    Evidence In vitro ubiquitylation assays, co-IP, siRNA knockdown stabilizing p73; ubiquitination assays and electrophysiology (mEPSC recordings) in hippocampal neurons for Munc13-1

    PMID:19581926 PMID:19996097

    Open questions at the time
    • Ubiquitin chain linkage type on p73 and Munc13-1 not specified
    • Whether PAM is required for all substrate ubiquitination events was not tested
  3. 2014 High

    Discovery that FBXO45 degrades the tumor suppressor Par-4 via its SPRY domain and interacts with N-cadherin through consensus motifs revealed dual substrate-recognition modes and an unexpected role in calcium-sensitive neuronal differentiation.

    Evidence Immunopurification-MS for Par-4, domain mutagenesis abolishing SPRY-dependent binding, apoptosis rescue with binding-deficient Par-4 mutant; MS screen identifying N-cadherin, calcium-dependent abrogation of interaction

    PMID:24992930 PMID:25143387

    Open questions at the time
    • Whether the N-cadherin interaction involves ubiquitin-ligase activity or a non-catalytic scaffolding role remained ambiguous
    • Consensus binding motif on Par-4 not fully mapped at the residue level
  4. 2015 High

    Demonstrating that the SPF complex targets four EMT-inducing transcription factors (ZEB2 via SPRY; SNAI1, SNAI2, TWIST1 via F-box) for K48-linked ubiquitination established FBXO45 as a major negative regulator of EMT and metastasis.

    Evidence Co-IP, ubiquitination assays, domain mutagenesis distinguishing SPRY vs. F-box recognition for different EMT-TFs

    PMID:25460509

    Open questions at the time
    • Whether all four EMT-TFs require PAM or whether FBXO45 can recruit alternative E3 ligases
    • Physiological context (which tissues use FBXO45 to restrain EMT in vivo) not defined
  5. 2015 Medium

    Finding that Hey1 translocates FBXO45 and PAM into the nucleus without itself being ubiquitinated revealed a non-degradative regulatory interaction and suggested FBXO45 ligase activity extends to nuclear substrates.

    Evidence TAP-MS, co-IP, subcellular localization of FBXO45 and PAM upon Hey1 expression

    PMID:26068074

    Open questions at the time
    • No nuclear substrate was identified in this study
    • Functional consequence of nuclear SPF complex not established
  6. 2018 High

    In vivo evidence that TNF-α disrupts FBXO45-Munc13-1 interaction in the spinal dorsal horn, causing Munc13-1 accumulation and neuropathic allodynia, linked the SPF complex to chronic pain pathophysiology.

    Evidence Co-IP, ubiquitination assay, spinal Fbxo45 siRNA knockdown, behavioral allodynia testing, electrophysiology, TNF-α neutralizing antibody

    PMID:30042425

    Open questions at the time
    • Direct TNF-α signaling event that disrupts FBXO45–Munc13-1 binding not identified
    • Whether FBXO45 downregulation is transcriptional or post-translational in neuropathic injury unclear
  7. 2019 High

    Showing that FBXO45-MYCBP2 degrades FBXW7 specifically during prolonged mitotic arrest revealed a cross-talk between two F-box proteins that determines the choice between mitotic slippage and mitotic cell death.

    Evidence Co-IP identifying a conserved acidic motif on FBXW7, ubiquitination assay, mitotic arrest and cell-fate analyses

    PMID:31285543

    Open questions at the time
    • Kinase responsible for FBXW7 recognition by FBXO45 during mitosis not identified
    • Whether this mechanism operates in tumors resistant to anti-mitotic drugs in vivo not tested
  8. 2020 High

    Demonstrating that FBXO45 is secreted by a nonclassical pathway and binds extracellular SPRY motifs of N-cadherin to promote radial neuronal migration in vivo expanded FBXO45 function beyond intracellular E3 ligase activity.

    Evidence Proximity ligation and affinity purification proteomics, in vivo cortical migration assays with SPRY-mutant N-cadherin and Fbxo45 shRNA

    PMID:32341084

    Open questions at the time
    • Mechanism of nonclassical secretion unknown
    • Whether extracellular FBXO45 retains ubiquitin-ligase activity or acts solely as a binding partner not resolved
  9. 2021 High

    Identification of IGF2BP1 ubiquitination at specific lysines (K190, K450) leading to IGF2BP1 activation (not degradation) and PLK1 upregulation revealed a non-degradative, activating ubiquitination mode driving liver tumorigenesis.

    Evidence Co-IP, site-specific ubiquitination mapping, transgenic mouse model, xenograft with epistasis (PLK1 inhibition, IGF2BP1 knockdown)

    PMID:34779401

    Open questions at the time
    • Ubiquitin chain linkage type on IGF2BP1 not specified
    • Whether FBXO45 acts through PAM/MYCBP2 for IGF2BP1 ubiquitination not shown
  10. 2021 Medium

    Discovery that the co-chaperone DNAJB9 stabilizes FBXO45 by suppressing its self-ubiquitination established a regulatory layer controlling FBXO45 protein levels and, consequently, ZEB1 degradation and EMT suppression.

    Evidence Co-IP, K48-specific ubiquitination assay, ectopic expression, in vivo metastasis model

    PMID:33966034

    Open questions at the time
    • Whether DNAJB9 acts via chaperone activity on FBXO45 folding or directly blocks the ubiquitination site is unclear
    • Other regulators of FBXO45 auto-ubiquitination not explored
  11. 2022 High

    Expansion of the substrate repertoire to USP49 (enhanced by NEK6 phosphorylation), GGNBP2, NP-STEP46 (K6-linked ubiquitination), and IFNLR1 showed that FBXO45 integrates kinase signaling to tune substrate recognition and regulates ERK signaling, innate antiviral immunity, and atypical ubiquitin linkages.

    Evidence Co-IP and ubiquitination assays with domain mapping (SPRY for USP49, GGNBP2); K6-linkage-specific ubiquitination for NP-STEP46; TurboID proximity labeling and site-specific IFNLR1 mutagenesis (K319R/K320R)

    PMID:35279684 PMID:35838331 PMID:36127399 PMID:36379255

    Open questions at the time
    • How NEK6-dependent phosphorylation of USP49 creates a degron recognized by FBXO45 SPRY domain is not structurally resolved
    • Physiological role of K6-linked polyubiquitination by FBXO45 beyond NP-STEP46 unknown
  12. 2024 High

    Demonstrating that FBXO45 recruits PPP6C phosphatase to UPF1 during S phase to stabilize replication-dependent histone mRNAs, and that FBXO45 loss causes histone insufficiency, chromatin relaxation, genomic instability, and malignant transformation, revealed a non-degradative, cell-cycle-regulated tumor-suppressive function distinct from its E3 ligase activity.

    Evidence AT2-specific knockout mouse developing spontaneous tumors, co-IP with PPP6C, phosphorylation assays, cell-cycle synchronization, CDK1-dependent FBXO45 degradation in S/G2

    PMID:39672818

    Open questions at the time
    • Whether FBXO45 phosphatase-adaptor and E3-ligase activities are mutually exclusive or coexist on the same complex
    • Structural basis for PPP6C recruitment by FBXO45 unknown
  13. 2025 Medium

    Discovery that FBXO45 ubiquitinates HIV-1 Tat (requiring S62 phosphorylation) and routes it to p62/SQSTM1-mediated autophagy established FBXO45 as an intrinsic antiviral restriction factor capable of suppressing HIV-1 replication and viral rebound.

    Evidence TurboID proximity labeling, co-IP, ubiquitination assay, S62A mutagenesis, autophagy flux assays, HIV-1 replication and rebound assays

    PMID:39936917

    Open questions at the time
    • Whether FBXO45-mediated Tat degradation occurs in primary CD4+ T cells and in vivo not shown
    • Ubiquitin chain type on Tat not determined
    • Whether PAM/MYCBP2 is required for Tat ubiquitination not tested
  14. 2025 Medium

    Identification of GPX4 and TFG as additional FBXO45 substrates linked FBXO45-driven ubiquitination to ferroptosis in diabetic endothelial cells and NF-κB-dependent invasion in TP53-mutant hepatocellular carcinoma, further broadening its disease relevance.

    Evidence SETD7 KO mice and AAV endothelial knockdown for GPX4 axis; co-IP with TFG K103 mutagenesis and orthotopic xenograft with rescue for TFG axis

    PMID:40275362 PMID:41030651

    Open questions at the time
    • Whether GPX4 degradation requires PAM/MYCBP2 not tested
    • TFG ubiquitination at K103 leads to stabilization rather than degradation—mechanism of stabilizing ubiquitination unexplained

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis of the SPF ternary complex, how FBXO45 selects among degradative, activating, and non-degradative ubiquitination outcomes for different substrates, the mechanism of its nonclassical secretion, and whether its phosphatase-adaptor and E3-ligase functions are coordinated or independent.
  • No crystal or cryo-EM structure of the SKP1-PAM-FBXO45 complex
  • Rules governing ubiquitin chain-type selection (K48 vs. K6 vs. activating) not defined
  • Nonclassical secretion mechanism completely uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 14 GO:0060090 molecular adaptor activity 2
Localization
GO:0005634 nucleus 2 GO:0005576 extracellular region 1 GO:0005829 cytosol 1
Pathway
R-HSA-392499 Metabolism of proteins 12 R-HSA-1266738 Developmental Biology 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-112316 Neuronal System 2 R-HSA-1640170 Cell Cycle 2 R-HSA-168256 Immune System 1 R-HSA-4839726 Chromatin organization 1 R-HSA-9612973 Autophagy 1
Partners
CDH2DNAJB9FBXW7MUNC13-1MYCBP2PPP6CSKP1UPF1
Complex memberships
SKP1-PAM/MYCBP2-FBXO45 (SPF)

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2009 FBXO45 does not form a canonical SCF complex due to an amino acid substitution in the consensus sequence for Cul1 binding; instead, it associates with PAM/Phr1 (a RING finger-type ubiquitin ligase) to form a novel FBXO45-PAM ubiquitin ligase complex required for neuronal development, synapse formation, and neuronal migration. Proteomics/mass spectrometry, co-immunoprecipitation, Fbxo45 knockout mice with phenotypic analysis Molecular and cellular biology High 19398581
2009 FBXO45 binds specifically to p73 and mediates its proteasome-dependent degradation via ubiquitylation both in vivo and in vitro; siRNA-mediated depletion of FBXO45 stabilizes p73 and induces p53-independent cell death. Co-immunoprecipitation, in vitro ubiquitylation assay, siRNA knockdown, proteasome inhibitor experiments Oncogene High 19581926
2009 FBXO45 ubiquitinates and promotes proteasomal degradation of the synaptic vesicle-priming factor Munc13-1; knockdown of Fbxo45 in hippocampal neurons increases the frequency of miniature excitatory postsynaptic currents. Ubiquitination assay, siRNA knockdown, electrophysiology (mEPSC recording) in primary cultured hippocampal neurons The Journal of biological chemistry High 19996097
2015 The atypical Skp1-PAM-FBXO45 (SPF) E3 ligase complex targets EMT-inducing transcription factors (Zeb2, Snai1, Snai2, Twist1) for ubiquitination and proteasomal degradation; FBXO45 recognizes Zeb2 through its SPRY domain and the other three EMT-TFs via its F-box domain, and K48-linked ubiquitination of Zeb2 requires a functional SBD domain. Co-immunoprecipitation, ubiquitination assays, domain mutagenesis, Western blotting Oncotarget High 25460509
2014 FBXO45 interacts with tumor suppressor Par-4 through its SPRY domain via a short consensus sequence motif, mediates Par-4 ubiquitylation and proteasomal degradation in the cytoplasm, and protects cancer cells from Par-4-induced apoptosis; a Par-4 mutant unable to bind FBXO45 is stabilized and enhances apoptosis. Immunopurification, mass spectrometry, co-IP, ubiquitination assay, RNAi knockdown, apoptosis assay, mutagenesis Cell death and differentiation High 24992930
2014 Fbxo45 interacts with N-cadherin through two consensus motifs overlapping the calcium-binding and dimerization sites; this interaction is abrogated by calcium treatment, and Fbxo45 inhibits calcium-sensitive proteolysis of N-cadherin to promote neuronal differentiation. Mass spectrometry-based proteomic screen, co-immunoprecipitation, RNAi knockdown, ectopic expression, neuronal differentiation assays The Journal of biological chemistry High 25143387
2019 FBXO45-MYCBP2 E3 ubiquitin ligase binds to a conserved acidic N-terminal motif of FBXW7 specifically during prolonged mitotic arrest, leading to FBXW7 ubiquitylation and proteasomal degradation, thereby promoting mitotic slippage and preventing mitotic cell death. Co-immunoprecipitation, ubiquitination assay, mitotic arrest experiments, protein stability assays Cell death and differentiation High 31285543
2020 Fbxo45 appears to be secreted by a nonclassical mechanism (not requiring a signal peptide or ER-to-Golgi transport) and binds SPRY motifs in the extracellular domain of N-cadherin that are not involved in cell-cell adhesion; SPRY motif mutation or Fbxo45 suppression inhibits radial neuronal migration in vivo. Proximity ligation proteomics, affinity purification proteomics, in vivo cortical migration assays with SPRY mutant N-cadherin and Fbxo45 shRNA Molecular and cellular biology High 32341084
2021 FBXO45 promotes IGF2BP1 ubiquitination at Lys190 and Lys450 sites, leading to IGF2BP1 activation and subsequent upregulation of PLK1 expression, thereby inducing cell proliferation and liver tumorigenesis; PLK1 inhibition or IGF2BP1 knockdown blocks FBXO45-driven tumorigenesis. Co-immunoprecipitation, ubiquitination assay with specific lysine mapping, transgenic mouse model, in vivo xenograft, epistasis experiments eLife High 34779401
2022 Fbxo45 binds USP49 through its SPRY domain and mediates USP49 ubiquitination and proteasomal degradation; this ubiquitination is enhanced by NEK6 kinase phosphorylation of USP49. Co-immunoprecipitation, ubiquitination assay, NEK6 kinase activity assay, xenograft mouse experiments Cell death & disease High 35279684
2022 Fbxo45 binds GGNBP2 via its SPRY domain and targets GGNBP2 for ubiquitination and proteasomal degradation in esophageal squamous cell carcinoma cells. Co-immunoprecipitation, ubiquitination assay, SPRY domain mutagenesis/interaction studies, xenograft mouse model Oncogene Medium 36127399
2022 FBXO45 binds IFNLR1 (IFN-λ receptor) intracellular domain and mediates its polyubiquitination and proteasomal degradation; K319R/K320R IFNLR1 mutant shows reduced polyubiquitination and greater stability; FBXO45 is induced by influenza infection and its silencing stabilizes IFNLR1. Proximity ligation biotin screen (TurboID), co-immunoprecipitation, ubiquitination assay, mutagenesis, siRNA knockdown The Journal of biological chemistry High 36379255
2021 DNAJB9 stabilizes FBXO45 protein by suppressing its self-ubiquitination, thereby enabling FBXO45-mediated Lys48-linked polyubiquitination and degradation of ZEB1 to inhibit EMT. Co-immunoprecipitation, ubiquitination assay (K48-specific), ectopic expression, in vivo metastasis assays Cell death & disease Medium 33966034
2022 Fbxo45 induces K6-linked polyubiquitination of nuclear NP-STEP46 (a striatal-enriched protein tyrosine phosphatase active form) leading to its proteasomal degradation in the nucleus, thereby sustaining aberrant ERK1/2 phosphorylation in NSCLC. In vitro and in vivo ubiquitination assays with K6-linkage specificity, nuclear fractionation, knockdown experiments, tumor growth assays Molecular oncology Medium 35838331
2015 Hey1 directly interacts with FBXO45 and induces translocation of FBXO45 and PAM into the nucleus; FBXO45 mediates indirect Hey1 binding to SKP1 but does not ubiquitinate Hey1; nuclear translocation may extend FBXO45 ligase activity to nuclear substrates. Tandem affinity purification, mass spectrometry, co-immunoprecipitation, subcellular localization experiments PloS one Medium 26068074
2018 Spinal TNF-α impedes Fbxo45-dependent Munc13-1 ubiquitination in the dorsal horn; neuropathic injury decreases spinal Fbxo45 expression and Fbxo45-Munc13-1 co-precipitation, leading to accumulation of Munc13-1 and increased synaptic excitability; focal Fbxo45 knockdown recapitulates neuropathic allodynia. Co-immunoprecipitation, ubiquitination assay, in vivo Fbxo45 knockdown (siRNA), behavioral testing, electrophysiology, TNF-α neutralizing antibody Cell death & disease High 30042425
2024 FBXO45 is a cell-cycle-regulated protein degraded by CDK1 phosphorylation during S/G2 phase; during S phase or DNA damage repair, FBXO45 binds UPF1 and recruits phosphatase PPP6C to inhibit UPF1 phosphorylation, preventing degradation of replication-dependent histone mRNAs and ensuring adequate histone supply; loss of FBXO45 causes histone insufficiency, chromatin relaxation, genomic instability, and malignant transformation. Knockout mouse model (AT2-specific), co-immunoprecipitation, phosphorylation assays, cell-cycle synchronization, genomic instability assays, clinical specimen analysis Cell death and differentiation High 39672818
2025 FBXO45 promotes Trk-fused gene (TFG) ubiquitination at Lys103, stabilizing TFG protein, which then facilitates binding of transcription factor ATF2, leading to upregulation of NF-κB p65 and promoting migration and invasion of TP53-mutant HCC cells. Co-immunoprecipitation, ubiquitination assay with site-specific mutagenesis (K103), orthotopic xenograft mouse model, TFG knockdown rescue JHEP reports Medium 41030651
2025 FBXO45 ubiquitinates HIV-1 Tat and directs it to SQSTM1/p62-mediated autophagic degradation; Tat phosphorylation at S62 is required for FBXO45-induced ubiquitination; FBXO45 silencing reduces p62 binding to Tat; FBXO45 overexpression suppresses HIV-1 replication and attenuates viral rebound after antiretroviral therapy withdrawal. TurboID proximity labeling, co-immunoprecipitation, ubiquitination assay, phosphorylation site mutagenesis (S62A), autophagy assays, HIV-1 replication assays Journal of virology Medium 39936917
2025 SETD7-mediated p53 mono-methylation activates FBXO45 transcription; FBXO45 in turn promotes GPX4 ubiquitination and degradation, leading to lipid peroxidation and oxidative stress in diabetic endothelial cells. SETD7 knockout mice, endothelial-specific AAV knockdown, co-immunoprecipitation, Western blotting, in vitro high-glucose model Cardiovascular diabetology Medium 40275362
2022 FBXO45 interacts with and ubiquitinates DUSP2, leading to its degradation and subsequent ERK1/2 activation, enhanced glycolysis, and increased cell viability in cervical cancer. Co-immunoprecipitation, ubiquitination assay, Western blotting, Seahorse metabolic assay, xenograft mouse model Naunyn-Schmiedeberg's archives of pharmacology Medium 40637745
2024 FBXO45 interacts with and mediates ubiquitination and proteasomal degradation of pro-apoptotic protein BIM, thereby inhibiting apoptosis and promoting breast cancer cell proliferation. Co-immunoprecipitation, ubiquitination assay, cycloheximide chase assay, apoptosis assay, xenograft mouse model BMC cancer Medium 38773471
2022 RBX1 directly binds FBXO45 and promotes its degradation and ubiquitination, thereby reducing FBXO45-mediated TWIST1 degradation and enhancing EMT and metastasis in triple-negative breast cancer. Co-immunoprecipitation, ubiquitination assay, knockdown experiments, Western blotting Aging Low 35802537

Source papers

Stage 0 corpus · 34 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2009 Fbxo45 forms a novel ubiquitin ligase complex and is required for neuronal development. Molecular and cellular biology 107 19398581
2009 The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 86 19581926
2015 Atypical ubiquitin E3 ligase complex Skp1-Pam-Fbxo45 controls the core epithelial-to-mesenchymal transition-inducing transcription factors. Oncotarget 80 25460509
2009 Fbxo45, a novel ubiquitin ligase, regulates synaptic activity. The Journal of biological chemistry 73 19996097
2021 Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation. eLife 59 34779401
2022 Fbxo45 facilitates pancreatic carcinoma progression by targeting USP49 for ubiquitination and degradation. Cell death & disease 56 35279684
2014 Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival. Cell death and differentiation 49 24992930
2021 DNAJB9 suppresses the metastasis of triple-negative breast cancer by promoting FBXO45-mediated degradation of ZEB1. Cell death & disease 44 33966034
2019 FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation. Cell death and differentiation 41 31285543
2020 FBXO45 is a potential therapeutic target for cancer therapy. Cell death discovery 32 32655893
2022 Fbxo45 promotes the malignant development of esophageal squamous cell carcinoma by targeting GGNBP2 for ubiquitination and degradation. Oncogene 31 36127399
2014 Fbxo45 inhibits calcium-sensitive proteolysis of N-cadherin and promotes neuronal differentiation. The Journal of biological chemistry 22 25143387
2022 CACNA1C-AS2 inhibits cell proliferation and suppresses cell migration and invasion via targeting FBXO45 and PI3K/AKT/mTOR pathways in glioma. Apoptosis : an international journal on programmed cell death 20 36038736
2020 Fbxo45 Binds SPRY Motifs in the Extracellular Domain of N-Cadherin and Regulates Neuron Migration during Brain Development. Molecular and cellular biology 18 32341084
2018 Spinal TNF-α impedes Fbxo45-dependent Munc13-1 ubiquitination to mediate neuropathic allodynia in rats. Cell death & disease 18 30042425
2005 Characterization of estrogen-induced F-box protein FBXO45. Oncology reports 18 16012741
2014 Novel rare variants in F-box protein 45 (FBXO45) in schizophrenia. Schizophrenia research 14 24878430
2022 Fbxo45-mediated NP-STEP46 degradation via K6-linked ubiquitination sustains ERK activity in lung cancer. Molecular oncology 13 35838331
2018 A genome-wide association study of coping behaviors suggests FBXO45 is associated with emotional expression. Genes, brain, and behavior 13 29665250
2022 The E3 ligase subunit FBXO45 binds the interferon-λ receptor and promotes its degradation during influenza virus infection. The Journal of biological chemistry 10 36379255
2022 E3 ubiquitin ligase RBX1 drives the metastasis of triple negative breast cancer through a FBXO45-TWIST1-dependent degradation mechanism. Aging 8 35802537
2015 Hey bHLH Proteins Interact with a FBXO45 Containing SCF Ubiquitin Ligase Complex and Induce Its Translocation into the Nucleus. PloS one 8 26068074
2025 SETD7 drives diabetic endothelial dysfunction through FBXO45-mediated GPX4 ubiquitylation. Cardiovascular diabetology 7 40275362
2023 LncRNA MEG8 ameliorates Parkinson's disease neuro-inflammation through miR-485-3p/FBXO45 axis. Acta neurologica Belgica 7 37814093
2022 MiR-30a-5p hampers proliferation of lung squamous cell carcinoma through targeting FBXO45. Histology and histopathology 5 35098525
2024 Fbxo45 facilitates the malignant progression of breast cancer by targeting Bim for ubiquitination and degradation. BMC cancer 4 38773471
2024 Loss of Fbxo45 in AT2 cells leads to insufficient histone supply and initiates lung adenocarcinoma. Cell death and differentiation 2 39672818
2025 The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis. Cancer discovery 1 39820335
2025 FBXO45 restricts HIV-1 replication by inducing SQSTM1/p62-mediated autophagic degradation of Tat. Journal of virology 1 39936917
2024 FBXO45 Knockdown Restrains the Progression of Bladder Cancer via the ERK/Cyclin D1/CDK4 Pathway. Archivos espanoles de urologia 1 39238305
2025 FBXO45 enhances cell viability and glycolysis in cervical cancer via DUSP2 ubiquitination-mediated ERK1/2 activation. Naunyn-Schmiedeberg's archives of pharmacology 0 40637745
2025 Elevated FBXO45 promotes TFG ubiquitination and drives lung metastasis of hepatocellular carcinoma. JHEP reports : innovation in hepatology 0 41030651
2025 Fbxo45 promotes cell viability, invasion and sunitinib resistance of clear cell renal cell carcinoma by targeting Erbin. Experimental cell research 0 41285235
2024 FBXO45 levels regulated ferroptosis renal tubular epithelial cells in a model of diabetic nephropathy by PLK1. Open medicine (Warsaw, Poland) 0 38841177